Decoding the pathological and genomic profile of epithelial ovarian cancer.

Autor: Rejaibi R; Pathology Department, Salah Azaiez Institute, Tunis, 1006, Tunisia.; Biology Department, Laboratory of Mycology, Pathologies and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, 2092, Tunisia.; Laboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université U105, Marseille, France.; Centre de Recherche en Cancérologie de Marseille, ICEP Platform, CRCM, Institut Paoli-Calmettes, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Marseille, France., Guille A; Laboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université U105, Marseille, France., Manai M; Laboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université U105, Marseille, France.; Laboratory of Transmission, Control, and Immunobiology of Infections, LR11IPT02 (LTCII), Tunis-Belvédère, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis, Tunisia., Adelaide J; Laboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université U105, Marseille, France., Agavnian E; Centre de Recherche en Cancérologie de Marseille, ICEP Platform, CRCM, Institut Paoli-Calmettes, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Marseille, France., Jelassi A; Pathology Department, Salah Azaiez Institute, Tunis, 1006, Tunisia.; Biology Department, Laboratory of Mycology, Pathologies and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, 2092, Tunisia., Doghri R; Pathology Department, Salah Azaiez Institute, Tunis, 1006, Tunisia.; Laboratory of Precision medicine personalized medicine and oncology investigation, Salah Azaiez Institute, Tunis, Tunisia., Charafe-Jauffret E; Centre de Recherche en Cancérologie de Marseille, ICEP Platform, CRCM, Institut Paoli-Calmettes, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Marseille, France.; CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Epithelial Stem Cells and Cancer Lab, Equipe labellisée LIGUE contre le cancer, Aix-Marseille Université, Marseille, France., Bertucci F; Laboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université U105, Marseille, France.; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Manai M; Biology Department, Laboratory of Mycology, Pathologies and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, 2092, Tunisia., Mrad K; Pathology Department, Salah Azaiez Institute, Tunis, 1006, Tunisia.; Laboratory of Precision medicine personalized medicine and oncology investigation, Salah Azaiez Institute, Tunis, Tunisia., Charfi L; Pathology Department, Salah Azaiez Institute, Tunis, 1006, Tunisia.; Laboratory of Precision medicine personalized medicine and oncology investigation, Salah Azaiez Institute, Tunis, Tunisia., Sabatier R; Laboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université U105, Marseille, France. sabatierr@ipc.unicancer.fr.; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France. sabatierr@ipc.unicancer.fr.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Nov 19; Vol. 14 (1), pp. 28573. Date of Electronic Publication: 2024 Nov 19.
DOI: 10.1038/s41598-024-80030-z
Abstrakt: Ovarian cancer (OC) is one of the most common cancers in women, with a high mortality rate. Most of published studies have been focused on Caucasian populations, with the need to explore biological features and clinical outcomes of patients from other ethnicities. We described clinical outcome (progression-free survival and overall survival) and biomarkers associated with survival in a cohort of patients with OC from Tunisia. Using immunohistochemistry, we assessed the expression of 14 proteins known to be altered in OC in a cohort of 198 patients. We explored the correlation between protein expression and copy number alteration (CNA) profiles. FIGO stage, menopausal status and mismatch repair deficiency were associated with survival. ERBB2 amplification was correlated with high ERBB2 expression (OR = 69.32, p = 4.03 E-09), and high PDL1 expression was associated to CD274 amplification (OR = 4.97, p = 5.79 E-2). We identified a correlation between survival and exposure to two CNA signatures (MAPK pathway and BRCA-related homologous recombination deficiency). Moreover, Gama-H2AX protein expression was correlated with exposure to a genomic signature associated with homologous recombination deficiency. We observed that OC clinical and pathological characteristics of these patients from Tunisia were similar to those of Caucasian patients. We identified frequent CNA in this population that need to be confirmed in other sets from Africa.
Competing Interests: Declarations Competing interests The authors declare no competing interests. Approval for human experiments Specimens for the EOC-TMA were gathered from the SAI. All patients willingly provided specimens, accompanied by written informed consent, and the study received approval from the Institutional Ethics Committee at SAI (Number 2150, September 2020). The methods employed adhered to pertinent guidelines and regulations. Our study adhered to the Code of Ethics of the World Medical Association (Declaration of Helsinki), as published in the British Medical Journal on July 18th, 1964. Ethics declarations Specimens for the EOC-TMA were gathered from the SAI. All patients willingly provided specimens, accompanied by written informed consent, and the study received approval from the Institutional Ethics Committee at SAI (Number 2150, September 2020). The methods employed adhered to pertinent guidelines and regulations. Our study adhered to the Code of Ethics of the World Medical Association (Declaration of Helsinki), as published in the British Medical Journal on July 18th, 1964. Informed consent was obtained from all subjects involved in the study.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: